Allergan and Editas Medicine Enter into Strategic R&D Alliance to Discover and Develop CRISPR Genome Editing … – GlobeNewswire (press release)
MedCity News |
Allergan and Editas Medicine Enter into Strategic R&D Alliance to Discover and Develop CRISPR Genome Editing …
GlobeNewswire (press release) The agreement covers early stage, first-in-class ocular programs targeting serious diseases based on Editas Medicine's unparalleled CRISPR genome editing platform, including CRISPR/Cas9 and CRISPR/Cpf1. Editas Medicine's lead program is being … Allergan and Editas announce $90M CRISPR deal Editas, Allergan Ink $90M CRISPR-Based Eye Drug Deal Allergan makes a deal with Editas to License CRISPR Programs for Eye Disease |
